Success Metrics

Completion Rate
0%(0/3)
Active Trials
4(40%)
Terminated
3(30%)

Phase Distribution

Ph phase_1
4
40%
Ph phase_2
2
20%
Ph not_applicable
1
10%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Terminated(3)
Other(3)

Detailed Status

Terminated3
Active, not recruiting3
unknown3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 22 (28.6%)
N/A1 (14.3%)

Trials by Status

recruiting110%
terminated330%
active_not_recruiting330%
unknown330%

Recent Activity

4 active trials
Showing 5 of 10
unknown

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

NCT03626285
active_not_recruitingphase_1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

NCT05088356
recruitingnot_applicable

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

NCT01189786
unknown

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

NCT01881334
active_not_recruitingphase_2

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

NCT01810588
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03626285

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

Unknown
NCT05088356Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Active Not Recruiting
NCT01189786Not Applicable

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

Recruiting
NCT01881334

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Unknown
NCT01810588Phase 2

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation

Active Not Recruiting
NCT02061800Phase 1

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Active Not Recruiting
NCT01745913Phase 2

Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

Terminated
NCT01050764Phase 1

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Terminated
NCT02026934

CliniMACS® CD34+ Reagent System for Expanded Access Use

Unknown
NCT00569179Phase 1

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

Terminated

All 10 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
10